Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Media Release
Novartis ranks first in 2024 Access to Medicine Index
The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration… -
Featured NewsOfficial partner of the Eurovision Song Contest 2025
We’re thrilled to announce that Novartis, a proudly Swiss company, is an official partner of the Eurovision Song Contest 2025, hosted in our headquarters city of Basel, Switzerland.
-
Key Release
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III… -
Story People and CultureCareers
My Journey to Novartis: Finding my Purpose and Passion
When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely different from what I was used to. But what sealed the deal for me was a conversation with my then manager who told me that the purpose I would feel and impact I would have would be unique. And she was right.
-
Key Release
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+… -
Media Release
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of…
-
Media Release
Novartis ranks first in 2024 Access to Medicine Index
The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration… -
Key Release
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III… -
Key Release
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+… -
Key Release
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +10% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +20% (kWk, +17% USD)Das Umsatzwachstum… -
Media Release
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of… -
Media Release
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and…
-
Key Release
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III… -
Key Release
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+… -
Key Release
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +10% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +20% (kWk, +17% USD)Das Umsatzwachstum… -
Key Release
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4… -
Key Release
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm,… -
Key Release
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+…
-
Featured News
Official partner of the Eurovision Song Contest 2025
We’re thrilled to announce that Novartis, a proudly Swiss company, is an official partner of the Eurovision Song Contest 2025, hosted in our headquarters city of Basel, Switzerland.
-
Featured News
Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
Novartis announced it has partnered with Versant Ventures (Versant) to form Borealis Biosciences (Borealis), an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases. xRNA, a core technology platform for Novartis, can target the body’s natural mRNA to modulate the production of proteins that cause disease.
-
Featured NewsOur next era
Novartis poised to expand impact on human health as it begins next era.
-
Featured News
Novartis’ Giving & Volunteering wins ACCP’s 2023 Corporate Social Impact Team of the Year Award
-
Featured NewsCreating positive social change through volunteering
Over 1 billion people volunteer worldwide, sharing their skills and experience, providing support within their communities, and offering emergency assistance to those in need. On International Volunteer Day (December 5), we join forces with the UN to recognize the tireless work of all volunteers and the contributions that they make.
-
Featured NewsWorld Sight Day 2022: Raising awareness on the importance of eye health
Through the Avoidable Blindness Program, Novartis is working with partners to strengthen eye health in sub-Saharan Africa.
-
Statement
Novartis statement on Maximum Fair Price for Entresto
-
Statement
Violence against innocent people runs counter to our work to improve human health
-
Statement
Novartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
Statement
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Statement
Novartis provides support for Moroccan earthquake victims
-
Statement
GT005 (PPY988): Development Program in Geographic Atrophy
-
Pulse Update
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
-
Pulse Update
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
-
Pulse Update
Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
-
Pulse Update
Novartis appoints Sloan Simpson as Global Head of Investor Relations
-
Pulse Update
Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
-
Pulse Update
FDA approves Novartis Millburn facility for US commercial production of Pluvicto®
-
Story People and CultureCareers
My Journey to Novartis: Finding my Purpose and Passion
When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely different from what I was used to. But what sealed the deal for me was a conversation with my then manager who told me that the purpose I would feel and impact I would have would be unique. And she was right.
-
Story Access to Healthcare
Negative impact of the IRA on patient access to innovative treatments
At Novartis, we are constantly pushing the limits of science to develop and deliver transformative medicines that fight disease and help people live life on their terms.
-
Story People and Culture
Every number has a story – my journey to Novartis as a Refugee
The current refugee crisis is one of the world's greatest humanitarian challenges. Svitlana shares her story of her journey to Novartis and how her work as part of the Giving and Volunteering team is opening the doors to refugees and other marginalized groups and allowing our people to make a difference by helping those who are most vulnerable.
-
Story People and Culture
Is Diversity, Equity and Inclusion (DEI) really that important?
We think so and here are just some of the reasons why: we believe our workplace should reflect today’s emerging workforce; every culture needs diversity to thrive; and it supports fair treatment and opportunities for all our people.
-
Story Discovery
A legacy of blood cancer innovation
Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.
-
Story People and Culture
A personal journey full circle, from curiosity about life on Earth to transformative therapies at Novartis
From curiosity about life on Earth to transformative therapies at Novartis. Michelle L Krishnan, Executive Director, MD PhD.
Novartis Financial Results – Q3 2024
Novartis announced the company’s financial results for the third quarter of 2024.
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
Annual Report 2023
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also contains our operating and financial results, accompanied by audited annual financial statements.
#NovartisNews
Tweets from the Media Relations team
